Blume Capital Management Inc. Raises Stake in Sanofi $SNY

Blume Capital Management Inc. increased its position in Sanofi (NASDAQ:SNY) by 315,725.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,266 shares of the company’s stock after buying an additional 25,258 shares during the period. Blume Capital Management Inc.’s holdings in Sanofi were worth $1,193,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of SNY. Oppenheimer Asset Management Inc. grew its stake in Sanofi by 7.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 179,209 shares of the company’s stock worth $8,459,000 after acquiring an additional 11,965 shares during the period. Waterfront Wealth Inc. grew its position in shares of Sanofi by 0.4% in the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after purchasing an additional 214 shares during the period. Lantz Financial LLC grew its position in shares of Sanofi by 3.1% in the third quarter. Lantz Financial LLC now owns 9,777 shares of the company’s stock valued at $461,000 after purchasing an additional 295 shares during the period. Smartleaf Asset Management LLC increased its stake in Sanofi by 18.5% in the third quarter. Smartleaf Asset Management LLC now owns 20,528 shares of the company’s stock valued at $937,000 after purchasing an additional 3,199 shares during the last quarter. Finally, Willis Investment Counsel lifted its position in Sanofi by 11.3% during the third quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock worth $26,276,000 after buying an additional 56,500 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Trading Up 0.7%

Shares of SNY stock opened at $47.83 on Monday. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The firm’s 50 day moving average price is $47.91 and its two-hundred day moving average price is $48.65. The stock has a market cap of $116.66 billion, a price-to-earnings ratio of 13.29, a price-to-earnings-growth ratio of 1.24 and a beta of 0.45.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SNY. Citigroup began coverage on shares of Sanofi in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.